𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas

✍ Scribed by Dr. José Santini; Dr. Jean-Louis Formento; Dr. Mireille Francoual; Dr. Gérard Milano; Dr. Maurice Schneider; Dr. Olivier Dassonville; Dr. François Demard


Publisher
John Wiley and Sons
Year
1991
Tongue
English
Weight
661 KB
Volume
13
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis


Epidermal growth factor (EGF) stimulates the growth of several types of epithelial tissues and possesses a strong mitogenic activity that is mediated through its cell surface receptor (EGFR). The aim of this study was to characterize EGFR and measure its levels in head and neck tumors biopsies (70 patients); use of a simplified competition technique with a radiolabeled ligand allowed evaluation of functional EGFR. Five samples (4 tumors and 1 control) were used to characterize EGF binding. Graphic representation identified a single family of binding sites. Kd values revealed high affinity for EGF binding: mean Kd, 0.156 f 0.1 08 nM (0.095-0.347 nM). EGF-binding characteristics (Kd) tion was found between EGFR levels and tumor size and stage. Controls exhibited a trend toward higher EGFR levels in elevated sizes and stages. According to a cutoff EGFR value of 100 frnol/rng protein, which separated all controls from tumors, EGFR-positive tumors (>lo0 fmol/mg protein) had a greater probability of complete response to chemotherapy than EGFRnegative tumors; other tumor characteristics, such as the degree of tumoral differentiation, tumor size, or stage, were unable to operate such a discrimination in the response to chemotherapy. EGFR may thus be an interesting biological marker for head and neck cancer. HEAD & NECK 1991;13:132-139 were similar in nontumoral tissue samples (controls) and in tumor material. In 59 of 60 cases, EGFR levels were higher in the tumor than in the corresponding controls. A significant correla-

Epidermal growth factor (EGF

) is a growth factor polypeptide with a molecular weight of 6,000 daltons, which was described by Cohen' in the mouse submaxillary gland. EGF stimulates the growth of several types of epithelial tissues and diated through its surface receptor (EGFR)* The intracellular component of EGFR is very similar to the V-erb p oncogene product2 In human cancer, the presence of EGFR has been reported in the b r e a ~t , ~* ~ lung: bladder,6 brain,7 ovaries,' thyroid,' and aerodigestive tract.lO." In these localizations, EGFR has been measured directly, by ligand-binding methods, or indirectly,


📜 SIMILAR VOLUMES


Epidermal growth factor receptor targete
✍ Mark E. Sharafinski; Robert L. Ferris; Soldano Ferrone; Jennifer R. Grandis 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 382 KB 👁 2 views

## Abstract ## Background Cumulative evidence implicates the epidermal growth factor receptor (EGFR) as an important therapeutic target in head and neck squamous cell carcinoma (HNSCC). The basis for the lack of correlation between EGFR expression in the HNSCC tumor and clinical responses to EGFR

Gene amplification and overexpression of
✍ Drs. Koichi Rikimaru; Drs. Keiko Tadokoro; Dr. Tadashi Yamamoto; Drs. Shoji Enom 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 552 KB

## Abstract The degree of gene amplification for epidermal growth factor receptor (EGFR) and its expression levels were examined in 4 cases of tumor lesions and their cell lines of human squamous cell carcinoma (SCC) of the oral cavity. The amplification was detected in 1 case (ZA), but not signifi

Radiolabeled cetuximab: Dose optimizatio
✍ Bianca A.W. Hoeben; Janneke D.M. Molkenboer-Kuenen; Wim J.G. Oyen; Wenny J.M. Pe 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 563 KB

## Abstract Noninvasive imaging of the epidermal growth factor receptor (EGFR) in head‐and‐neck squamous cell carcinoma could be of value to select patients for EGFR‐targeted therapy. We assessed dose optimization of ^111^Indium‐DTPA‐cetuximab (^111^In‐cetuximab) for EGFR imaging in a head‐and‐neck

Defects in the opioid growth factor rece
✍ Patricia J. McLaughlin; Brendan C. Stack Jr.; Roger J. Levin; Fred Fedok; Ian S. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 541 KB

## Abstract ## BACKGROUND The endogenous opioid peptide, [Met^5^]‐enkephalin, termed opioid growth factor (OGF), interacts with its receptor (OGFr) to play a role as a constitutively expressed inhibitory growth factor in the proliferation of epithelial cells. This study compared protein and gene e

Vascular endothelial growth factor C and
✍ Csilla Neuchrist; Bohan M. Erovic; Allesandra Handisurya; Michael B. Fischer; Ge 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 379 KB 👁 1 views

## Abstract ## Background and Methods. VEGF proteins and their receptors are involved in tumor vessel neoformation. The third VEGF receptor, VEGFR3 (flt‐4) is important during both blood vessel development and lymphatic vessel formation. Because HNSCC preferentially metastasizes to regional lymph